Design Therapeutics (DSGN) Preferred Shares Issued (2020 - 2021)
Design Therapeutics' (DSGN) quarterly Preferred Shares Issued came in at $124.7 million in Q1 2021, up 179.0% year-on-year from $44.7 million in Q1 2020, and up 402196.77% quarter-over-quarter from $31000.0 in Q2 2020.
Design Therapeutics (DSGN) Preferred Shares Issued (2020 - 2021) Analysis & Trends
Design Therapeutics has disclosed Preferred Shares Issued across 2 years of filings, most recently posting $124.7 million for Q1 2021.
- Preferred Shares Issued for Q1 2021 came in at $124.7 million, up 179.0% year-over-year; the trailing twelve-month figure through Dec 2021 was $124.7 million (up 178.8% YoY), and the FY2021 annual result was $124.7 million, up 178.8% from the prior year.
- Preferred Shares Issued came in at $124.7 million for Q1 2021 at Design Therapeutics, up from $31000.0 in the prior quarter.
- In the past five years, Preferred Shares Issued ranged from a high of $124.7 million in Q1 2021 to a low of $31000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Design Therapeutics | 763.94 Mn | 541.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 124.71 Mn |
| Mar 31, 2021 | 124.71 Mn |
| Jun 30, 2020 | 31,000.00 |
| Jun 30, 2020 | 31,000.00 |
| Mar 31, 2020 | 44.70 Mn |
| Mar 31, 2020 | 44.70 Mn |